| human | Q5 |
| P2038 | ResearchGate profile ID | Natalia_Bogdanova |
| P108 | employer | Hannover Medical School | Q911561 |
| P734 | family name | Bogdanova | Q35958218 |
| Bogdanova | Q35958218 | ||
| Bogdanova | Q35958218 | ||
| P735 | given name | Natalia | Q6296301 |
| Natalia | Q6296301 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q57250674 | A common coding variant in CASP8 is associated with breast cancer risk |
| Q29417084 | A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
| Q57305942 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer |
| Q39235192 | Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma |
| Q38406780 | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study |
| Q52647897 | Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. |
| Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
| Q36073563 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression |
| Q39198367 | Analysis of a RECQL splicing mutation, c.1667_1667+3delAGTA, in breast cancer patients and controls from Central Europe |
| Q44712404 | Apoptosis gene polymorphisms and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy |
| Q30276986 | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes |
| Q47195947 | Assessment of a FBXW8 frameshift mutation, c.1312_1313delGT, in breast cancer patients and controls from Central Europe |
| Q40381692 | Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer |
| Q64251151 | Assessment of the role of translationally controlled tumor protein 1 (TPT1/TCTP) in breast cancer susceptibility and ATM signaling |
| Q37684409 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
| Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
| Q39423088 | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
| Q92377257 | BARD1 is A Low/Moderate Breast Cancer Risk Gene: Evidence Based on An Association Study of the Central European p.Q564X Recurrent Mutation |
| Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
| Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
| Q34793437 | CYP2B6*6 is associated with increased breast cancer risk |
| Q35782435 | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer |
| Q35668946 | Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk |
| Q36490507 | Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q29417145 | Common variants at 19p13 are associated with susceptibility to ovarian cancer |
| Q36255665 | Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q34342248 | Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q46168959 | Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations |
| Q38720533 | Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci |
| Q24633316 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer |
| Q36487146 | Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk |
| Q57250672 | Erratum: Corrigendum: A common coding variant in CASP8 is associated with breast cancer risk |
| Q57319395 | Erratum: Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer |
| Q36966218 | Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study |
| Q35653910 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
| Q47549687 | Exome sequencing and case-control analyses identify RCC1 as a candidate breast cancer susceptibility gene |
| Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
| Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q45258410 | First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study |
| Q34979715 | Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium |
| Q51208799 | Frameshift variant FANCL*c.1096_1099dupATTA is not associated with high breast cancer risk. |
| Q59237374 | Frequency of CHEK2 gene mutations in breast cancer patients from Republic of Bashkortostan |
| Q33859206 | Functional deficiency of NBN, the Nijmegen breakage syndrome protein, in a p.R215W mutant breast cancer cell line |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q34031757 | Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q36956156 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer |
| Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
| Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
| Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
| Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q37202841 | Genome-wide association study for ovarian cancer susceptibility using pooled DNA. |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q24645441 | Genome-wide association study identifies novel breast cancer susceptibility loci |
| Q33778612 | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. |
| Q36276527 | Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer |
| Q40053289 | Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q33356511 | Hereditary breast cancer: ever more pieces to the polygenic puzzle |
| Q33330850 | Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q37006170 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. |
| Q30252854 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q37684424 | Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q45874785 | Inhibitor-immunology-study. Evaluation of inhibitor development in haemophilia B. |
| Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
| Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q114182490 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
| Q37181547 | Molecular genetics of breast and ovarian cancer: recent advances and clinical implications |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q34460831 | Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer |
| Q37499453 | Mutation analysis of the ERCC4/FANCQ gene in hereditary breast cancer |
| Q33320072 | Mutation analysis of the MDM4 gene in German breast cancer patients |
| Q51431905 | Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer. |
| Q26799669 | Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk |
| Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
| Q43773075 | Nijmegen Breakage Syndrome mutations and risk of breast cancer |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q37079859 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing |
| Q47847793 | Nonsense mutation p.Q548X in BLM, the gene mutated in Bloom's syndrome, is associated with breast cancer in Slavic populations |
| Q35795253 | PALB2 mutations in German and Russian patients with bilateral breast cancer |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q37353838 | PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations |
| Q112572520 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes |
| Q43290572 | Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthra |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
| Q33921008 | Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium |
| Q34483516 | Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). |
| Q96431220 | Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q44242400 | Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from Central and Eastern Europe |
| Q51116126 | Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe. |
| Q34212196 | Prostate cancer risk is not altered by TP53AIP1 germline mutations in a German case-control series |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
| Q36009422 | RAD51B in Familial Breast Cancer |
| Q40728414 | Rare ATAD5 missense variants in breast and ovarian cancer patients |
| Q46760859 | Rare occurrence of PALB2 mutations in ovarian cancer patients from the Volga-Ural region |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
| Q37624504 | Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10 |
| Q36089391 | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer |
| Q61118451 | Shared heritability and functional enrichment across six solid cancers |
| Q64004349 | Shared heritability and functional enrichment across six solid cancers |
| Q43425193 | Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk |
| Q43813974 | TGFB1 gene polymorphism Leu10Pro (c.29T>C), prostate cancer incidence and quality of life in patients treated with brachytherapy |
| Q34408038 | TOPBP1 missense variant Arg309Cys and breast cancer in a German hospital-based case-control study |
| Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
| Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
| Q57755117 | The frequency of the BLM*p.Q548X (c.1642C > T) mutation in breast cancer patients from Russia |
| Q62583324 | The frequency of the BLM*p.Q548X (c.1642C > T) mutation in breast cancer patients from Russia |
| Q35024008 | The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing |
| Q59237272 | The search for new candidate genes involved in ovarian cancer pathogenesis by exome sequencing |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q92994868 | Two truncating variants in FANCC and breast cancer risk |
| Q56342454 | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility |
| Q49710400 | [The search for new candidate genes involved in ovarian cancer pathogenesis by exome sequencing]. |
| Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
| Q56334023 | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology |
Search more.